<p>, /PRNewswire/ -- Akso Health Group (NASDAQ: AHG)（&#34;Akso Health&#34;或&#34;公司&#34;）今天宣布启动其下一代专有脑机接口（BCI）技术的研发项目。公司正在建立必要的基础研发基础设施，以开发和商业化 BCI 技术，公司认为这代表了 21 世纪最具变革性和高价值的技术前沿之一。</p>
<p>AHG 正在开发超高分辨率神经传感、实时人工智能神经解码和下一代接口设计的专有创新，相关专利申请正在进行中。公司打算将其 BCI 项目工程化，以满足神经科学、先进治疗和人机交互等领域的未满足需求，前提是成功的研究、开发和监管流程。</p>
<p>Akso Health Group 首席执行官 Yilin (Linda) Wang 表示：&#34;这一战略举措标志着我们为 AHG 建立新的长期增长引擎的努力的开始。我们正在投资于我们认为在全球神经技术市场竞争所必需的基础研发和知识产权。我们承诺将严格遵循所有适用法规，追求这一目标。&#34;</p>
<p><strong>警示声明</strong></p>
<p>公司尚未开始任何人类临床试验，未向 FDA 或任何其他监管机构提交任何监管申请，也未从与 BCI 相关的活动中产生任何收入。不能保证任何产品候选者将成功开发、获得监管机构批准或商业化。投资者不应对本公告中的前瞻性声明过于依赖。</p>
<p><strong>关于 Akso Health Group</strong></p>
<p>Akso Health Group（NASDAQ: AHG），前身为小白买买公司，目前专注于在中国和美国销售医疗设备，并在美国进行某些放射治疗肿瘤中心相关的运营。2024 年 3 月，公司间接收购了天津德医汇互联网医院和天津德医汇诊所有限公司的股权，这些机构提供初步诊断、后续咨询和慢性病管理的在线医疗咨询服务。</p>
<p><strong>安全港声明</strong></p>
<p>本公告包含根据 1934 年证券交易法第 21E 条款的定义的前瞻性声明。这些前瞻性声明是在 1995 年美国私人证券诉讼改革法的&#34;安全港&#34;条款下作出的。这些声明可以通过&#34;将会&#34;、&#34;预计&#34;、&#34;预期&#34;、&#34;未来&#34;、&#34;打算&#34;、&#34;计划&#34;、&#34;相信&#34;、&#34;估计&#34;、&#34;潜在&#34;、&#34;继续&#34;、&#34;正在进行&#34;、&#34;目标&#34;、&#34;指导&#34;和类似表述来识别。公司还可能在其定期报告中、向美国证券交易委员会（&#34;SEC&#34;）的年度报告中、新闻稿和其他书面材料中，以及公司高管、董事或员工向第三方作出的口头声明中作出书面或口头的前瞻性声明。任何非历史事实的声明，包括关于公司信念和期望的声明，都是前瞻性声明，涉及可能导致实际结果与前瞻性声明中的结果有重大差异的因素、风险和不确定性。这些因素和风险包括但不限于以下内容：与我们获得设备、技术、许可和人才的能力相关的风险，以令人满意的条款发展医疗设备业务和/或启动计划中的医疗保健业务（如果有的话）；与公司适应并进行必要调整以有效竞争和运营的能力相关的风险；与医疗保健领域政府政策的决策或变化相关的风险；与竞争加剧和新竞争服务的发展相关的风险；我们可能无法及时开发或实现医疗和健康服务的商业成功的风险，或根本无法实现；与相关司法管辖区的监管要求或执法以及医疗保健系统或医疗支付系统结构变化相关的风险；与我们成功整合和从任何我们许可或收购的技术中获得利益的能力相关的风险；与我们对业务、运营结果和财务状况的预测相关的风险；与我们产品和服务的潜在市场机会相关的风险；以及与医疗相关服务的监管监督不确定性、对未获批准医疗产品的推广或商业化的限制相关的风险；任何评估的服务模型可能无法超越探索阶段的风险；医疗服务安排的风险、对医疗相关服务的推广或交付的限制、对第三方医疗提供者的不确定性，以及预期的合作可能无法超越初步或框架阶段的风险。有关这些和其他风险、不确定性或因素的进一步信息包含在公司向 SEC 提交的文件中。本公告中提供的所有信息截至本公告日期为最新，公司不承担更新该信息的任何义务，除非法律要求。</p>
<p>欲了解更多信息，请访问 http://www.ahgtop.com/en/index.html</p>
<p>如需投资者咨询，请联系：</p>
<p><strong>Akso Health Group</strong></p>
<p><strong>投资者关系</strong></p>
<p><strong>电子邮件：ir@ahgtop.com</strong></p>
<p><strong>网站：</strong> <strong>www.ahgtop.com</strong></p>
<p>来源：Akso Health Group</p>

小白买买

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

医疗业 ETF - Vanguard

标普医疗保健服务 ETF - SPDR

美国医疗保健供应商 ETF - iShares

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

<p>Akso Health Group（纳斯达克代码：AHG）宣布启动一项专有的脑机接口（BCI）研发计划，旨在开发变革性的神经技术。该计划将重点关注神经传感、人工智能神经解码和接口设计的创新，目前正在申请专利。首席执行官王怡琳强调了这一举措对全球神经技术市场长期增长的战略重要性。然而，公司尚未开始人类临床试验，也未从 BCI 活动中产生收入，并且没有成功产品开发或获得监管批准的保证</p>

<p>, /PRNewswire/ -- Akso Health Group (NASDAQ: AHG) (&#34;Akso Health&#34; or the &#34;Company&#34;) today announced the commencement of its next-generation, proprietary Brain-Computer Interface (BCI) technology research and development program. The Company is establishing the foundational R&amp;D infrastructure necessary to develop and commercialize BCI technology, which it believes represents one of the most transformative and high-value technology frontiers of the 21st century.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Akso Health Group (NASDAQ: AHG)（&#34;Akso Health&#34;或&#34;公司&#34;）今天宣布启动其下一代专有脑机接口（BCI）技术的研发项目。公司正在建立必要的基础研发基础设施，以开发和商业化 BCI 技术，公司认为这代表了 21 世纪最具变革性和高价值的技术前沿之一。</p>
</div><p>AHG is developing proprietary innovations in ultra-high-resolution neural sensing, real-time AI neural decoding, and next-generation interface design, with patent applications pending. The Company intends to engineer its BCI program to address unmet needs across neuroscience, advanced therapeutics, and human-machine interaction, subject to successful research, development, and regulatory processes.</p>
<div class="lb-trans"><p>AHG 正在开发超高分辨率神经传感、实时人工智能神经解码和下一代接口设计的专有创新，相关专利申请正在进行中。公司打算将其 BCI 项目工程化，以满足神经科学、先进治疗和人机交互等领域的未满足需求，前提是成功的研究、开发和监管流程。</p>
</div><p>Yilin (Linda) Wang, Chief Executive Officer of Akso Health Group, stated, &#34;This strategic initiative marks the beginning of our effort to build a new, long-term growth engine for AHG. We are investing in the foundational R&amp;D and intellectual property we believe will be necessary to compete in the global neurotechnology market. We are committed to pursuing it rigorously and in full compliance with all applicable regulations.&#34;</p>
<div class="lb-trans"><p>Akso Health Group 首席执行官 Yilin (Linda) Wang 表示：&#34;这一战略举措标志着我们为 AHG 建立新的长期增长引擎的努力的开始。我们正在投资于我们认为在全球神经技术市场竞争所必需的基础研发和知识产权。我们承诺将严格遵循所有适用法规，追求这一目标。&#34;</p>
</div><p><strong>Cautionary Statement</strong></p>
<div class="lb-trans"><p><strong>警示声明</strong></p>
</div><p>The Company has not commenced any human clinical trials, has not made any regulatory submissions to the FDA or any other regulatory authority, and is not generating any revenue from BCI-related activities. There can be no assurance that any product candidate will be successfully developed, approved by regulators, or commercialized. Investors should not place undue reliance on forward-looking statements in this release.</p>
<div class="lb-trans"><p>公司尚未开始任何人类临床试验，未向 FDA 或任何其他监管机构提交任何监管申请，也未从与 BCI 相关的活动中产生任何收入。不能保证任何产品候选者将成功开发、获得监管机构批准或商业化。投资者不应对本公告中的前瞻性声明过于依赖。</p>
</div><p><strong>About Akso Health Group</strong></p>
<div class="lb-trans"><p><strong>关于 Akso Health Group</strong></p>
</div><p>Akso Health Group (NASDAQ: AHG), formerly known as Xiaobai Maimai Inc., currently specializes in the sales of medical devices in China and in the United States and also conducts certain radiotherapy oncology center-related operations in the United States. In March 2024, the Company indirectly acquired equity interests in Tianjin Deyihui Internet Hospital and Tianjin Deyihui Clinic Co., Ltd., which provide online medical consultations for initial diagnosis, follow-up consultations, and management of chronic diseases.</p>
<div class="lb-trans"><p>Akso Health Group（NASDAQ: AHG），前身为小白买买公司，目前专注于在中国和美国销售医疗设备，并在美国进行某些放射治疗肿瘤中心相关的运营。2024 年 3 月，公司间接收购了天津德医汇互联网医院和天津德医汇诊所有限公司的股权，这些机构提供初步诊断、后续咨询和慢性病管理的在线医疗咨询服务。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the &#34;safe harbor&#34; provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as &#34;will,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;future,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;believes,&#34; &#34;estimates,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;ongoing,&#34; &#34;targets,&#34; &#34;guidance&#34; and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the &#34;SEC&#34;), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: risks related to our ability to obtain equipment, technology, license and talents at satisfactory terms to grow the medical equipment business and/or to start the planned healthcare business, if at all; risks related to the Company's ability to adapt and make the necessary adjustments to compete and operate effectively; risks related to decisions or changes in governmental policies in the healthcare segment; risks related to increased competition and the development of new competing services; the risk that we may be unable to develop or achieve commercial success for our medical and healthcare services in a timely manner, or at all; risks related to regulatory requirements or enforcement in relevant jurisdiction and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to successfully integrate and derive benefits from any technologies that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; and risks related to uncertainties in regulatory oversight of healthcare-related services, limitations on the promotion or commercialization of unapproved medical products; risks that any evaluated service models may not progress beyond exploratory stages; risks on healthcare service arrangements, limitations on the promotion or delivery of medical-related services, uncertainties regarding third-party medical providers, and the risk that contemplated collaborations may not progress beyond preliminary or framework stages. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the SEC. All information provided in this announcement is current as of the date of this announcement, and the Company does not undertake any obligation to update such information, except as required under applicable law.</p>
<div class="lb-trans"><p>本公告包含根据 1934 年证券交易法第 21E 条款的定义的前瞻性声明。这些前瞻性声明是在 1995 年美国私人证券诉讼改革法的&#34;安全港&#34;条款下作出的。这些声明可以通过&#34;将会&#34;、&#34;预计&#34;、&#34;预期&#34;、&#34;未来&#34;、&#34;打算&#34;、&#34;计划&#34;、&#34;相信&#34;、&#34;估计&#34;、&#34;潜在&#34;、&#34;继续&#34;、&#34;正在进行&#34;、&#34;目标&#34;、&#34;指导&#34;和类似表述来识别。公司还可能在其定期报告中、向美国证券交易委员会（&#34;SEC&#34;）的年度报告中、新闻稿和其他书面材料中，以及公司高管、董事或员工向第三方作出的口头声明中作出书面或口头的前瞻性声明。任何非历史事实的声明，包括关于公司信念和期望的声明，都是前瞻性声明，涉及可能导致实际结果与前瞻性声明中的结果有重大差异的因素、风险和不确定性。这些因素和风险包括但不限于以下内容：与我们获得设备、技术、许可和人才的能力相关的风险，以令人满意的条款发展医疗设备业务和/或启动计划中的医疗保健业务（如果有的话）；与公司适应并进行必要调整以有效竞争和运营的能力相关的风险；与医疗保健领域政府政策的决策或变化相关的风险；与竞争加剧和新竞争服务的发展相关的风险；我们可能无法及时开发或实现医疗和健康服务的商业成功的风险，或根本无法实现；与相关司法管辖区的监管要求或执法以及医疗保健系统或医疗支付系统结构变化相关的风险；与我们成功整合和从任何我们许可或收购的技术中获得利益的能力相关的风险；与我们对业务、运营结果和财务状况的预测相关的风险；与我们产品和服务的潜在市场机会相关的风险；以及与医疗相关服务的监管监督不确定性、对未获批准医疗产品的推广或商业化的限制相关的风险；任何评估的服务模型可能无法超越探索阶段的风险；医疗服务安排的风险、对医疗相关服务的推广或交付的限制、对第三方医疗提供者的不确定性，以及预期的合作可能无法超越初步或框架阶段的风险。有关这些和其他风险、不确定性或因素的进一步信息包含在公司向 SEC 提交的文件中。本公告中提供的所有信息截至本公告日期为最新，公司不承担更新该信息的任何义务，除非法律要求。</p>
</div><p>For more information, please visit http://www.ahgtop.com/en/index.html</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 http://www.ahgtop.com/en/index.html</p>
</div><p>For investor inquiries, please contact:</p>
<div class="lb-trans"><p>如需投资者咨询，请联系：</p>
</div><p><strong>Akso Health Group</strong></p>
<div class="lb-trans"><p><strong>Akso Health Group</strong></p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p><strong>Email: ir@ahgtop.com</strong></p>
<div class="lb-trans"><p><strong>电子邮件：ir@ahgtop.com</strong></p>
</div><p><strong>Website:</strong> <strong>www.ahgtop.com</strong></p>
<div class="lb-trans"><p><strong>网站：</strong> <strong>www.ahgtop.com</strong></p>
</div><p>SOURCE Akso Health Group</p>
<div class="lb-trans"><p>来源：Akso Health Group</p>
</div>

AHG Announces Initiation of World-Class, Proprietary Brain-Computer Interface R&D Program - Targeting the Next Frontier of Human Neurotechnology | AHG Stock News

AHG 宣布启动世界级的专有脑机接口研发计划，目标是人类神经技术的下一个前沿 | AHG 股票新闻